Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aurinia Pharm Ord
(NQ:
AUPH
)
6.810
-0.090 (-1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
Next >
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
June 25, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
June 14, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Results of the 2021 Annual General Meeting
June 07, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
June 07, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
May 20, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 14, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
May 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
May 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
May 06, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
April 28, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 15, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
April 08, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.